Pfizer extends tender offer to acquire Icagen

NEW YORK — After entering a definitive agreement to acquire biopharmaceutical company Icagen, Pfizer has extended its tender offer for all outstanding shares of common stock.

Pfizer, which already has an 11% stake in Icagen, is offering the company a cash transaction of $6 per share. The tender offer, which was extended to Icagen through Pfizer's wholly owned subsidiary Eclipse Acquisition, expires at midnight on Sept. 1.

All other terms and conditions of the tender offer remain unchanged.